Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01950039 · ClinicalTrials.gov registry record · Phase 2
Metabolic Effects of Betaine Supplementation
A Phase 2 study of Obesity and Dysglycemia, sponsored by Joslin Diabetes Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT01950039 is a Phase 2 study of Obesity and Dysglycemia that has completed, run by Joslin Diabetes Center. The registered enrollment target is 28 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01950039, a Phase 2 study of Obesity and Dysglycemia, has completed, sponsored by Joslin Diabetes Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
Betaine is important in cellular metabolic pathways. Few epidemiologic studies link betaine levels to diabetes and cardiovascular disease. Small human studies suggest benefit for non-alcoholic liver disease. In this study we will determine if administration of betaine improves metabolic measures, liver fat and/or endothelial function in humans with glucose intolerance who are overweight.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Betaine
Study Locations (1)
Massachusetts
- Joslin Diabetes Center and Brigham and Womens Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2014-01 |
| Est. Completion | 2018-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01950039
The ClinicalTrials.gov registry entry for NCT01950039 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (97% lower). The listed sponsor is Joslin Diabetes Center, which has 73 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01950039 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01950039 about?
NCT01950039 is a clinical study titled "Metabolic Effects of Betaine Supplementation". Betaine is important in cellular metabolic pathways. Few epidemiologic studies link betaine levels to diabetes and cardiovascular disease. Small human studies suggest benefit for non-alcoholic liver disease. In this study we will determine if administration of betaine improves metabolic measures, li...
What is the current status of trial NCT01950039?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2014-01. Estimated completion is 2018-08.
What conditions does trial NCT01950039 study?
This clinical trial studies the following conditions: Obesity, Dysglycemia.
What interventions are being tested in trial NCT01950039?
The interventions under investigation include: Placebo (DRUG), Betaine (DRUG).
Who is sponsoring clinical trial NCT01950039?
This trial is sponsored by Joslin Diabetes Center, which has 73 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01950039 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
Convergent Mechanisms Underlying Reprometabolic Syndrome in Women
RECRUITING · Phase 2
-
Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
RECRUITING · Phase 2
-
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
RECRUITING · Phase 2
-
Pharmacological and Behavioral Treatment After Bariatric Surgery
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.